Large vision foundation models have been widely adopted for retinal disease classification without systematic evidence justifying their parameter requirements. In the present work we address two critical questions: First, are large domain-specific foundation models essential, or do compact general-purpose architectures suffice? Second, does specialized retinal pretraining justify its computational cost? To answer this, we benchmark initialization strategies across four retinal imaging classification tasks spanning Optical Coherence Tomography (OCT) and Color Fundus Photography (CFP) modalities: 8-class OCT classification, 3-class diabetic macular edema (DME), 5-class diabetic retinopathy (DR), and 3-class glaucoma (GL) detection. We evaluate 12-13 model configurations per task, including vision transformers (22.8M-86.6M parameters), Swin Transformers (27.6M-28.3M), ConvNeXt (28.6M), and the domain-specific RETFound models (303M), under identical training conditions. Our results challenge prevailing assumptions: First, we demonstrate that pretraining provides universal benefits (5.18-18.41% improvement), scaling with task difficulty. Second, compact architectures (27-29M) dominate Pareto frontiers; SwinV2-tiny achieves top-1 performance on three datasets. Third, RETFound (303M) justifies its computational cost only for challenging DR grading (accuracy of 71.15%), while ImageNet pretraining proves to be sufficient with all other tasks (DME accuracy: 99.24%, OCT accuracy: 97.96%). CFP tasks show larger pretraining accuracy gains (9.13-18.41%) than OCT (5.18%). Thus, the evidence suggests that compact general-purpose models deliver near-optimal performance for most retinal classification tasks; specialized foundation models warranted only for fine-grained discrimination under extreme class imbalance.

Diabetic macular edema (DME) is a severe complication of diabetes, characterized by thickening of the central portion of the retina due to accumulation of fluid. DME is a significant and common cause of visual impairment in diabetic patients. Center-involved DME (ci-DME) is the highest risk form of disease because fluid extends close to the fovea which is responsible for sharp central vision. Earlier diagnosis or prediction of ci-DME may improve treatment outcomes. Here, we propose an ensemble method to predict ci-DME onset within a year, after using synthetic ultra-wide field color fundus photography (UWF-CFP) images provided by the DIAMOND Challenge during development. We adopted a variety of baseline state-of-the-art classification networks including ResNet, DenseNet, EfficientNet, and VGG with the aim of enhancing model robustness. The best performing models were Densenet-121, Resnet-152 and EfficientNet-b7, and these were assembled into a definitive predictive model. The final ensemble model demonstrates a strong performance with an Area Under Curve (AUC) of 0.7017, an F1 score of 0.6512, and an Expected Calibration Error (ECE) of 0.2057 when deployed on the synthetic test dataset. Results from our ensemble model were superior/comparable to previous recorded results in highly curated settings using conventional fundus photography/ultra-wide field fundus photography. Optimal sensitivity in previous studies (using humans or computers to diagnose) ranges from 67.3%-98%, specificity from 47.8%-80%. Therefore, our method can be used safely and effectively in a range of settings may facilitate earlier diagnosis, better treatment decisions, and improved prognostication in ci-DME.

Optical coherence tomography (OCT) is a non-invasive imaging technique with extensive clinical applications in ophthalmology. OCT enables the visualization of the retinal layers, playing a vital role in the early detection and monitoring of retinal diseases. OCT uses the principle of light wave interference to create detailed images of the retinal microstructures, making it a valuable tool for diagnosing ocular conditions. This work presents an open-access OCT dataset (OCTDL) comprising over 1600 high-resolution OCT images labeled according to disease group and retinal pathology. The dataset consists of OCT records of patients with Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Epiretinal Membrane (ERM), Retinal Artery Occlusion (RAO), Retinal Vein Occlusion (RVO), and Vitreomacular Interface Disease (VID). The images were acquired with an Optovue Avanti RTVue XR using raster scanning protocols with dynamic scan length and image resolution. Each retinal b-scan was acquired by centering on the fovea and interpreted and cataloged by an experienced retinal specialist. In this work, we applied Deep Learning classification techniques to this new open-access dataset.

Mediation analysis learns the causal effect transmitted via mediator variables between treatments and outcomes and receives increasing attention in various scientific domains to elucidate causal relations. Most existing works focus on point-exposure studies where each subject only receives one treatment at a single time point. However, there are a number of applications (e.g., mobile health) where the treatments are sequentially assigned over time and the dynamic mediation effects are of primary interest. Proposing a reinforcement learning (RL) framework, we are the first to evaluate dynamic mediation effects in settings with infinite horizons. We decompose the average treatment effect into an immediate direct effect, an immediate mediation effect, a delayed direct effect, and a delayed mediation effect. Upon the identification of each effect component, we further develop robust and semi-parametrically efficient estimators under the RL framework to infer these causal effects. The superior performance of the proposed method is demonstrated through extensive numerical studies, theoretical results, and an analysis of a mobile health dataset.

In ophthalmology, intravitreal operative medication therapy (IVOM) is a widespread treatment for diseases related to the age-related macular degeneration (AMD), the diabetic macular edema (DME), as well as the retinal vein occlusion (RVO). However, in real-world settings, patients often suffer from loss of vision on time scales of years despite therapy, whereas the prediction of the visual acuity (VA) and the earliest possible detection of deterioration under real-life conditions is challenging due to heterogeneous and incomplete data. In this contribution, we present a workflow for the development of a research-compatible data corpus fusing different IT systems of the department of ophthalmology of a German maximum care hospital. The extensive data corpus allows predictive statements of the expected progression of a patient and his or her VA in each of the three diseases. We found out for the disease AMD a significant deterioration of the visual acuity over time. Within our proposed multistage system, we classify the VA progression into the three groups of therapy "winners", "stabilizers", and "losers" (WSL scheme). Our OCT biomarker classification using an ensemble of deep neural networks results in a classification accuracy (F1-score) of over 98 %, enabling us to complete incomplete OCT documentations while allowing us to exploit them for a more precise VA modelling process. Our VA prediction requires at least four VA examinations and optionally OCT biomarkers from the same time period to predict the VA progression within a forecasted time frame, whereas our prediction is currently restricted to IVOM / no therapy. While achieving a prediction accuracy of up to 69 % (macro average F1-score) when considering all three WSL-based progression groups, this corresponds to an improvement by 11.2 % in comparison to our ophthalmic expertise (57.8 %).

We study differentially private distributed optimization under communication constraints. A server using SGD for optimization aggregates the client-side local gradients for model updates using distributed mean estimation (DME). We develop a communication-efficient private DME, using the recently developed multi-message shuffled (MMS) privacy framework. We analyze our proposed DME scheme to show that it achieves the order-optimal privacy-communication-performance tradeoff resolving an open question in [1], whether the shuffled models can improve the tradeoff obtained in Secure Aggregation. This also resolves an open question on the optimal trade-off for private vector sum in the MMS model. We achieve it through a novel privacy mechanism that non-uniformly allocates privacy at different resolutions of the local gradient vectors. These results are directly applied to give guarantees on private distributed learning algorithms using this for private gradient aggregation iteratively. We also numerically evaluate the private DME algorithms.

Clinical diagnosis of the eye is performed over multifarious data modalities including scalar clinical labels, vectorized biomarkers, two-dimensional fundus images, and three-dimensional Optical Coherence Tomography (OCT) scans. Clinical practitioners use all available data modalities for diagnosing and treating eye diseases like Diabetic Retinopathy (DR) or Diabetic Macular Edema (DME). Enabling usage of machine learning algorithms within the ophthalmic medical domain requires research into the relationships and interactions between all relevant data over a treatment period. Existing datasets are limited in that they neither provide data nor consider the explicit relationship modeling between the data modalities. In this paper, we introduce the Ophthalmic Labels for Investigating Visual Eye Semantics (OLIVES) dataset that addresses the above limitation. This is the first OCT and near-IR fundus dataset that includes clinical labels, biomarker labels, disease labels, and time-series patient treatment information from associated clinical trials. The dataset consists of 1268 near-IR fundus images each with at least 49 OCT scans, and 16 biomarkers, along with 4 clinical labels and a disease diagnosis of DR or DME. In total, there are 96 eyes' data averaged over a period of at least two years with each eye treated for an average of 66 weeks and 7 injections. We benchmark the utility of OLIVES dataset for ophthalmic data as well as provide benchmarks and concrete research directions for core and emerging machine learning paradigms within medical image analysis.

By Jeffrey R. Willis, Associate Medical Director at Genentech Published 20 August 2019 (this article first appeared on gene.com) Artificial intelligence (AI) is expected to have a dramatic impact on medicine by improving our ability to diagnose disease and select the best treatments for individual patients. In a proof-of-concept study published in the March Investigative Ophthalmology & Visual Sciences, we have shown how this technology could revolutionise the way ophthalmologists diagnose diabetic macular edema (DME), a complication of diabetes that causes a thickening of the retina that can lead to irreversible blindness if left untreated. Tragically, many people lose their sight to DME in the prime of their lives, making it harder for them to work and care for themselves. The rising prevalence of diabetes has a direct correlation on new cases of DME.

Diabetic eye disease is one of the fastest growing causes of preventable blindness. With the advent of anti-VEGF (vascular endothelial growth factor) therapies, it has become increasingly important to detect center-involved diabetic macular edema. However, center-involved diabetic macular edema is diagnosed using optical coherence tomography (OCT), which is not generally available at screening sites because of cost and workflow constraints. Instead, screening programs rely on the detection of hard exudates as a proxy for DME on color fundus photographs, often resulting in high false positive or false negative calls. To improve the accuracy of DME screening, we trained a deep learning model to use color fundus photographs to predict DME grades derived from OCT exams. Our "OCT-DME" model had an AUC of 0.89 (95% CI: 0.87-0.91), which corresponds to a sensitivity of 85% at a specificity of 80%. In comparison, three retinal specialists had similar sensitivities (82-85%), but only half the specificity (45-50%, p<0.001 for each comparison with model). The positive predictive value (PPV) of the OCT-DME model was 61% (95% CI: 56-66%), approximately double the 36-38% by the retina specialists. In addition, we used saliency and other techniques to examine how the model is making its prediction. The ability of deep learning algorithms to make clinically relevant predictions that generally require sophisticated 3D-imaging equipment from simple 2D images has broad relevance to many other applications in medical imaging.

Google's AI subsidiary DeepMind is getting serious about ethics. The UK-based company, which Google bought in 2014, today announced the formation of a new research group dedicated to the thorniest issues in artificial intelligence. These include the problems of managing AI bias; the coming economic impact of automation; and the need to ensure that any intelligent systems we develop share our ethical and moral values. DeepMind Ethics & Society (or DMES, as the new team has been christened) will publish research on these topics and others starting early 2018. The group has eight full-time staffers at the moment, but DeepMind wants to grow this to around 25 in a year's time.